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ABSTRACT Signal transductions by the dual-function
CXCR4 and CCR5 chemokine receptorsyHIV type 1 (HIV-1)
coreceptors were electrophysiologically monitored in Xenopus
laevis oocytes that also coexpressed the viral receptor CD4 and
a G protein-coupled inward-rectifying K1 channel (Kir 3.1).
Large Kir 3.1-dependent currents generated in response to the
corresponding chemokines (SDF-1a for CXCR4 and MIP-1a;
MIP-1b and RANTES for CCR5) were blocked by pertussis
toxin, suggesting involvement of inhibitory guanine nucleo-
tide-binding proteins. Prolonged exposures to chemokines
caused substantial but incomplete desensitization of re-
sponses with time constants of 5–7 min and recovery time
constants of 12–19 min. CXCR4 and CCR5 exhibited heter-
ologous desensitization in this oocyte system, suggesting pos-
sible inhibition of a common downstream step in their sig-
naling pathways. In contrast to chemokines, perfusion with
monomeric or oligomeric preparations of the glycoprotein of
Mr 120,000 (gp120) derived from several isolates of HIV-1 did
not activate signaling by CXCR4 or CCR5 regardless of CD4
coexpression. However, adsorption of the gp120 from a T-cell-
tropic virus resulted in CD4-dependent antagonism of CXCR4
response to SDF-1a, whereas gp120 from macrophage-tropic
viruses caused CD4-dependent antagonism of CCR5 response
to MIP-1a. These antagonisms could be partially overcome by
high concentrations of chemokines and were specific for
coreceptors of the corresponding HIV-1 isolates, suggesting
that they resulted from direct interactions of gp120–CD4
complexes with coreceptors and that they did not involve the
desensitization pathway. These results indicate that mono-
meric or oligomeric gp120s specifically antagonize CXCR4
and CCR5 signaling in response to chemokines, but they do
not exclude the possibility that gp120s might also function as
weak agonists in some cells. The gp120-mediated disruption of
CXCR4 and CCR5 signaling may contribute to AIDS patho-
genesis.
Fusion of the viral membrane with the cell surface membrane
during infection by HIV type 1 (HIV-1) involves collaboration
between the CD4 receptor and a coreceptor (1–6). Corecep-
tors are seven transmembrane G protein-coupled receptors for
proinflammatory chemokines. The major coreceptor for mac-
rophage-tropic (M-tropic) HIV-1 isolates is CCR5, which is
activated by the chemokines MIP-1a, MIP-1b, and RANTES,
whereas that for T-cell-tropic HIV-1 isolates is CXCR4, which
is activated by SDF-1 (7). The gp120 envelope glycoprotein
(glycoprotein of apparent Mr 120,000) of HIV-1 forms a
ternary complex with CD4 and coreceptors that displaces
125I-labeled chemokines (8–13).
The roles of chemokine receptor signaling in HIV-1 infec-
tion remain uncertain. Several mutations in CCR5 and
CXCR4 that prevent G protein activation do not perturb their
coreceptor activities (14, 15), suggesting that virus-induced
activation of these chemokine receptors cannot be essential for
infection. Nevertheless, evidence reported during preparation
of this manuscript indicated that monomeric or oligomeric
gp120s derived from several M-tropic isolates of HIV-1 could
induce CCR5-mediated Ca21 mobilization and chemotaxis in
a proportion of activated CD4-positive human T lymphocytes
(16). However, similar glycoprotein preparations from other
immunodeficiency viruses that also use CCR5 failed to activate
signaling. Moreover, gp120 preparations from T-cell-tropic
viruses did not activate signaling by CXCR4. These results
imply that gp120 shed from nests of cells infected with some
M-tropic HIV-1 might chemoattract uninfected CD4- and
CCR5-positive cells or enhance their susceptibilities to infec-
tion or to apoptotic stimuli. Another recent report indicated
that gp120s from various T-cell-tropic or M-tropic HIV-1
isolates did not induce detectable Ca21 mobilization in acti-
vated CD4-positive T lymphocytes, despite the substantial
responses of these same cells to chemokines (17). However,
this group detected significant gp120-mediated increases in
tyrosine phosphorylation of Pyk2 tyrosine kinase and pre-
sented evidence that this response depended on CXCR4 and
CCR5. The implications of these results are discussed below.
A potential complication in this field derives from evidence
that gp120 binding to CD4 in T lymphocytes can activate the
associated Lck tyrosine kinase, with resultant activation of the
Raf-mitogen-activated protein kinase pathway and of tran-
scription factors including NF-kB (18–20). In lymphocytes and
other cells, tyrosine kinase-signaling events can cause G
protein-independent Ca21 mobilization with resultant Pyk2
activation (21, 22) or chemotaxis (23). Moreover, signal trans-
duction by chemokine receptors also activates src family
tyrosine kinases and mitogen-activated protein kinases (22, 24,
25). Because of the likelihood of overlap and cross-talk
between the gp120-activated Lck and chemokine receptor-
signaling pathways, thorough understanding of gp120 signaling
will ultimately require controlled studies of cells that lack
either or both of these pathways. In addition, the assays such
as Ca21 mobilization that have been commonly used to study
chemokine receptor signaling generally appear to have high
backgrounds and poor signal-to-noise ratios. As one approach
toward analyzing these issues, we developed a sensitive system
in which chemokine receptor signaling in Xenopus oocytes is
coupled to a G protein-activated inward-rectifying K1 channel
(Kir 3.1; refs. 26 and 27). Kir 3.1 is a high conductivity channel
that is promiscuously activated by Gbg-subunits (28–31).
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Xenopus oocytes lack CD4, Lck, and chemokine receptors but
contain many heterotrimeric G proteins and have been widely
used to study chemokine receptors and other G protein-
coupled receptors (32–34). Our results suggest that this system
may be exceptionally useful for quantitatively and directly
monitoring G protein activation by CXCR4 and CCR5. In this
system, gp120s were CD4-dependent and tropism-specific
antagonists of CXCR4 and CCR5 responses to chemokines.
MATERIALS AND METHODS
Reagents and cDNA Clones. Chemokines were from Pep-
roTech (Rocky Hill, NJ) and pertussis toxin was from Calbio-
chem. Monomeric T-cell-tropic gp120 (IIIB) was donated by
Shiu-lok Hu (Bristol-Myers Squibb). Monomeric M-tropic
gp120 Ba-L was a gift from Ray Sweet (SmithKline Beecham)
and oligomeric JR-FL gp120 in a complex with the extracel-
lular domain of gp41 was provided by James Arthos and
Anthony Fauci (National Institute of Allergy and Infectious
Diseases, Bethesda). Full-length SDF-1 was provided by Ian
Clark-Lewis (University of British Columbia, Vancouver).
Vectors and cDNA clones were gifts of the following investi-
gators; Kir 3.1, Henry Lester (California Institute of Technol-
ogy, Pasadena, CA); mGluR 2, Shigetada Nakanishi (Kyoto
University); pBF expression vector, John Adelman (The Vol-
lum Institute); CXCR4 cDNA, Frank R. Jirik (University of
British Columbia, Vancouver); CCR5 cDNA, John P. Moore
(Aaron Diamond Research Institute, New York). CD4 poly-
clonal antibody was obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Disease, and was contrib-
uted by Michael Phelan.
125I-gp120 Binding to Xenopus Oocytes and HeLa Cells.
Samples (10–25 mg) of gp120 were labeled with [125I]Bolton-
Hunter reagent (ICN), and aliquots were adsorbed onto
oocytes in a frog Ringer’s solution 96 mM NaCly2 mM KCly1.8
mM CaCl2y1 mM MgCl2y5 mM Hepes (pH 7.5) for 1–2 h at
room temperature with gentle shaking. Each oocyte was then
separately washed for 5 min in Ringer’s solution and counted
in a gamma counter. Binding of a constant trace amount of
125I-gp120 onto HeLa and HeLa-CD4 cells (clone H1-J) (35)
was done in the presence of various concentrations of unla-
beled gp120 for times indicated at 37°C.
Oocyte Expression. Stage V–VI oocytes were collected from
anesthetized Xenopus laevis and defolliculated with collage-
nase (Boehringer Mannheim). Oocytes were incubated at 16°C
in frog Ringer’s solution supplemented with 2.5 mM sodium
pyruvate (Sigma), 0.5 mM theophylline (Sigma), and 50 mgyml
gentamycin (Life Technologies, Grand Island, NY). cDNAs
were subcloned into oocyte expression vectors (pOG-1 or
pBF) at a site between 59- and 39-untranslated Xenopus
b-globin sequences (36). Linearized plasmids were transcribed
in vitro with T7 or SP6 polymerase, and 5–50 ng of capped
cRNA were microinjected into oocytes on the day of harvest.
Membranes were isolated from oocytes and western immuno-
blotting was done with a sheep anti-human CD4 antiserum or
a rabbit antiserum to CCR5 (37).
Electrophysiology. Electrophysiological recording was done
2–5 d after cRNA injection. Two-electrode voltage clamp was
performed with a GeneClamp 500 amplifier interfaced to a
Digidata 1200 AyD (Axon Instruments, Foster City, CA). The
interface was controlled with an IBM-compatible computer
running PCLAMP, version 6.0 (Axon Instruments, Foster City,
CA). Microelectrodes were filled with 3 M KCl and had tip
resistances of 0.1–1.5 MV. The oocytes were placed in a small
chamber continually perfused with high K1 Ringer’s solution
[100 mM KCly2 mM NaCly1.8 mM CaCl2y1 mM MgCl2y5 mM
Hepes (pH 7.5)]. Agonists and blockers were applied by bath
perfusion. The holding potential was set at 230 mV and
current–voltage records were obtained during 250-ms voltage
jumps to potentials between 140 and 2100 mV. Desensitiza-
tion kinetics were determined by least squares fit to single
exponential functions. Kinetics of recovery from desensitiza-
tion were determined by measuring the responses in different
oocytes at specific intervals. The responses were then normal-
ized to the peak response and fitted to an exponential function.
Where indicated, oocytes were incubated with 1 mgyml per-
tussis toxin in Ringer’s solution for 48 h before recording.
RESULTS
Chemokine-Induced Activation of Kir 3.1 in Xenopus Oo-
cytes. Capped cRNAs for chemokine receptors and Kir 3.1
were coinjected into oocytes, and voltage clamp current re-
cordings were obtained 2–3 d after injection. Oocytes were
clamped at 230 mV in high K1–Ringer’s solution, and varying
concentrations of receptor agonists were applied by bath
perfusion. Because glutamate is known to activate Kir 3.1
through binding to the G protein-coupled metabotropic glu-
tamate receptor mGluR 2 (34), we used this receptor as a
control. This response saturated at glutamate concentrations
of 50–100 mM with half-maximal stimulation at 5.96 6 1.43
mM (n 5 4; results not shown). As shown in Fig. 1A, the inward
currents induced by SDF-1a in oocytes expressing CXCR4
were also concentration dependent. Saturation was reached
between 10 and 30 nM SDF-1a with a half-maximal stimula-
tion at 2.84 6 0.57 nM (n 5 3). Similarly, MIP-1a activated
CCR5 (Fig. 1B) with half-maximal activation at 0.94 6 0.04 nM
MIP-1a (n 5 3). In addition, the CCR5 agonists MIP-1b and
RANTES activated currents in oocytes expressing this recep-
tor with half-maximal stimulations at 0.33 6 0.04 nM (n 5 3)
and 4.0 6 0.65 nM (n 5 3), respectively. The activities of these
FIG. 1. Left traces: Activation of currents in oocytes coexpressing
Kir 3.1 with CXCR4 (A) and CCR5 (B). Inward currents were seen
in response to superfusion of ligands for the duration indicated by the
bar above the trace. The holding potential was 230 mV, and the
recording solutions were K1–Ringer’s solution containing 100 mM
KCl. Right plots: Concentration dependence of currents. Data were
fitted to a rectangular hyperbola, yielding the following EC50 values for
each ligand: SDF-1a, 2.8 6 0.6 nM (n 5 3); MIP-1a, 0.9 6 0.04 (n 5
3). (C) Inhibition of CXCR4yKir 3.1-mediated currents by pertussis
toxin (PTX) pretreatment (1 mgyml, 48 h) or BaCl2 (100 mM). Each
point represents mean 6 SEM, n 5 4. (D) Reversal potential (Erev)
of currents produced by 3 nM SDF-1a in oocytes coexpressing Kir 3.1
and CXCR4 depends on external K1 concentrations. Line shown is
least squares fit (54 mVydecade) through points representing mean 6
SEM (n 5 3).
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agonists were specific, because concentrations of 10 nM
MIP-1a did not induce currents in oocytes coexpressing Kir 3.1
and CXCR4 (n 5 2). Conversely, 10 nM SDF-1a did not
induce currents in oocytes that coexpressed Kir 3.1 and CCR5
(n 5 7). Control uninjected oocytes and oocytes lacking
chemokine receptors or Kir 3.1 did not show any currents when
the ligands were applied (data not shown). Protein immuno-
blots confirmed the presence of CCR5 in membranes of
oocytes that had been injected with this cRNA (data not
shown).
To verify that the currents induced by chemokine applica-
tion resulted from activation of the G protein-dependent K1
channel Kir 3.1, we characterized the properties of these
currents. The voltage dependencies of currents induced by
activation of mGluR 2, CXCR4, and CCR5 showed strong
inward rectification at all agonist concentrations, as expected
for Kir 3.1 (33). This is illustrated in Fig. 1C, which shows the
current–voltage curve for CXCR4 activation by 1 nM SDF-1a.
These data also show strong inhibition of these currents by the
K1 channel blocker Ba21 and their abolishment by pertussis
toxin. In addition, the reversal potentials of currents induced
by 3 nM SDF-1a changed by 54.2 mV per 10-fold change in
extracellular K1, close to the prediction of the Nernst equation
for a K-selective conductance (Fig. 1D). These data show that
the currents induced in oocytes by chemokine applications
resulted from activation of Kir 3.1 by specific G protein
receptor-signaling pathways.
Desensitization of Chemokine Receptor Signaling. The cur-
rents induced by 10 mM L-Glu in oocytes that coexpressed
mGluR 2 and Kir 3.1 are further analyzed in Fig. 2A. Gluta-
mate-dependent currents desensitized during prolonged ago-
nist application with a time constant of 7.5 6 1.2 min (n 5 5),
to a steady-state value representing 44.3 6 5.1% of the initial
response. Fig. 2B shows a response of the CCR5 receptor to a
prolonged application of 10 nM MIP-1a. The response de-
cayed with a time constant of 5.3 6 0.4 min (n 5 11) to 46.7 6
6.0% of the initial response. Similarly, prolonged application
of 10 nM SDF-1a resulted in attenuation of the CXCR4
response to 23.2 6 2.7% of the initial value with a time
constant of 6.1 6 0.6 min (n 5 10) (Fig. 2C). Following
washout of agonists, the responses recovered slowly from
desensitization. The time constant for recovery of CXCR4
following steady-state desensitization induced by SDF-1a was
12.8 6 1.7 min, and the time constant for CCR5 recovery after
desensitization with MIP-1a was approximately 18.7 6 4.4
min.
Cross-desensitization in oocytes coexpressing CXCR4 and
CCR5 together with Kir 3.1 was also apparent. Fig. 2C shows
that brief nondesensitizing applications of MIP-1a induced
similar current amplitudes. Following a prolonged exposure to
SDF-1a that resulted in desensitization of the CXCR4 re-
sponse, the CCR5 response to MIP-1a was also desensitized.
This cross-desensitization by SDF-1a in oocytes coexpressing
CXCR4, CCR5, and Kir 3.1 resulted in inhibition of CCR5
responses to MIP-1a by 50.2 6 5.9% (n 5 6). Conversely,
desensitization with MIP-1a inhibited SDF-1a activation of
CXCR4 by 66.0 6 9.5% (n 5 4). Similarly, desensitization with
SDF-1a in oocytes that coexpressed CXCR4, mGluR 2, and
Kir 3.1 inhibited L-Glu activation of mGluR 2 by 23.8 6 5.5%
(n 5 4), whereas desensitization with L-Glu inhibited SDF-1a
activation of CXCR4 by 84 6 5.9% (n 5 3). This heterologous
desensitization suggests the involvement of effectors down-
stream of receptor activation including G proteins andyor ion
channels.
Effects of HIV-1 gp120 on Signal Transduction by CXCR4
and CCR5. The gp120s used in this investigation were highly
purified (e.g., see Fig. 3A Inset) and were active in binding to
oocytes that had been injected with CD4 cRNA (Fig. 3A) as
well as to human HeLa–CD4 cells but not to control HeLa cells
(Fig. 3B). The latter data also show the kinetics at which
different concentrations of monomeric gp120 saturate CD4 on
surfaces of Hela–CD4 cells. Abundant expression of CD4 in
oocyte membranes was also demonstrated by protein immu-
FIG. 2. Desensitization of chemokine and glutamate receptors. (A)
Decay of inward current during continued application of 10 mM L-Glu
(indicated by bar above trace) and partial recovery following washout
of agonist in a representative oocyte coexpressing mGluR 2 and Kir
3.1. (B) Similar homologous desensitization of CCR5 chemokine
receptor response during long exposure to MIP-1a. (C) Heterologous
desensitization of CCR5 response by prolonged CXCR4 activation in
oocytes coinjected with CXCR4, CCR5, and Kir 3.1 cRNA.
FIG. 3. (A) 125I-gp120 IIIB binding to Xenopus oocytes. 125I-gp120
IIIB (1.2 3 106 cpmyml) was used for binding to one batch of oocytes
that coexpressed combinations of Kir 3.1 with mGluR 2, CD4, and
CXCR4 as well as to uninjected control oocytes (**P , 0.0001; *P ,
0.0024 by the Student’s unpaired t test). Each column represents
mean 6 SEM for five determinations. (Inset) 125I-gp120 was analyzed
by gel electrophoresis followed by autoradiography. Different amounts
were loaded onto the two lanes. (B) 125I-gp120 IIIB binding to
HeLa–CD4 (clone H1-J) and to control HeLa cells. Cell cultures were
incubated at 37°C with 125I-gp120 IIIB for various times in the presence
of unlabeled gp120 IIIB at a concentration of 16 nM (F) or 64 nM (E).
Nonspecific background was determined by incubating HeLa cells
lacking CD4 with the same amount of 125I-gp120 IIIB in the absence
of unlabeled gp120 IIIB (h). C and D demonstrate that HIV-1 gp120
IIIB and JR-FL do not induce currents in oocytes coexpressing CD4
and Kir 3.1 with their respective coreceptors. (C) An inward current
was produced by application of 3 nM SDF-1a to a representative
oocyte coexpressing CD4, CXCR4, and Kir 3.1. Application of 16 nM
monomeric gp120 IIIB did not induce a current and also did not reduce
the subsequent SDF-1a activation of CXCR4. (K1–Ringer’s solution,
membrane potential 5 230 mV). (D) Similar experiment showing lack
of effect of JR-FL gp120 in a representative oocyte coexpressing CD4,
CCR5, and Kir 3.1. An inward current was observed during application
of 10 nM MIP-1a, but brief application of 20 nM oligomeric JR-FL
gp120 did not induce a current or reduce the magnitude of the
subsequent response to MIP-1a.
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noblotting (results not shown). To determine whether gp120
induces a signal when it binds to CD4 and the coreceptor, we
tested highly purified T-cell-tropic gp120 IIIB as well as
M-tropic oligomeric gp120 JR-FL and monomeric gp120 Ba-L
in the K1 channel activation assay. As shown in Fig. 3C, no
currents were generated in response to perfusion of HIV-1
gp120 IIIB (16 nM) onto voltage-clamped oocytes coexpress-
ing CD4, CXCR4, and Kir 3.1. This was substantiated with a
total of 39 oocytes from 14 batches. Moreover, the currents
induced by SDF-1a did not decrease after short applications
(30–90 s) of gp120 IIIB. Similarly, M-tropic oligomeric gp120
from the JR-FL isolate of HIV-1 was perfused onto oocytes
that coexpressed CD4, CCR5, and Kir 3.1. An inward current
was induced when 10 nM MIP-1a was applied, whereas
M-tropic gp120 (20 nM) did not elicit any currents in the same
oocyte, and brief applications of JR-FL gp120 did not decrease
subsequent MIP-1a activation of CCR5 (Fig. 3D). Identical
results were obtained in 12 oocytes from three different
batches. In addition, the monomeric M-tropic Ba-L gp120 also
failed to induce signals in oocytes that had been coinjected
with cRNAs for CD4, CCR5, and Kir 3.1 (n 5 3). Superfusion
of gp120 onto voltage-clamped oocytes for longer times (10–20
min) was similarly ineffective at inducing currents in oocytes
that were coinjected with cRNAs that encode CD4, respective
coreceptors, and Kir 3.1 (data not shown).
We then examined effects of prolonged preincubations with
high concentrations of T-cell-tropic as well as M-tropic gp120s
on chemokine receptor signaling. Saturating concentrations of
highly purified gp120 IIIB were incubated for 1–2 h with
oocytes that coexpressed CD4, CXCR4, CCR5, and Kir 3.1
before voltage clamping. Similar to results with short applica-
tions, preadsorption of gp120 IIIB did not activate a significant
baseline K1 current [slope conductances at 295 mV were
6.3 6 0.5 (n 5 20) and 6.9 6 0.3 (n 5 19) for control and gp120
treated oocytes, respectively]. However, this preincubation
with T-cell-tropic gp120 IIIB significantly decreased SDF-1a-
induced currents compared with untreated control oocytes
(Fig. 4A, top tracings; P , 0.02; n 5 30), without affecting
MIP-1a-induced currents (Fig. 4A, bottom tracings). Similarly,
oocytes that were preincubated for 2 h with a saturating
concentration of oligomeric M-tropic JR-FL gp120 had sig-
nificantly decreased responses to MIP-1a compared with the
untreated control oocytes (Fig. 4B, top right; P , 0.02; n 5 4),
whereas the SDF-1a-induced currents in the same oocytes did
not change (Fig. 4B, bottom tracings). These inhibitory effects
were completely dependent on CD4 expression in the oocytes
(results not shown).
Similar analyses were then done over wide ranges of che-
mokine concentrations. As shown in Fig. 4C, extensive pread-
sorption with gp120 IIIB significantly decreased SDF-1a ac-
tivation of CXCR4 at all concentrations compared with the
control oocytes. However, this inhibition of signaling was
proportionately greater at lower concentrations of SDF-1a.
Specifically, the inhibition was 80% at 0.1 nM SDF-1a and
approximately 20% at 5 nM SDF-1a. In contrast, extensive
preadsorption of gp120 IIIB had no significant effect on CCR5
responses to MIP-1a in these same oocytes. These results
confirm the specificity of the gp120 IIIB inhibition and suggest
that a competitive mechanism may be involved in the inhibition
of CXCR4 activation by SDF-1a. A similar analysis was also
done with monomeric gp120 from M-tropic Ba-L isolate, with
nearly identical results (see Fig. 4D). In this case, the inhibition
was specific for CCR5 responses to MIP-1a and was greatest
when the concentration of MIP-1a was low. The Ba-L gp120
had no significant effect on CXCR4-signaling responses to
SDF-1a in these same oocytes.
DISCUSSION
Chemokine Receptor Signaling. In oocytes that coexpressed
CXCR4 and CCR5 with the G protein-coupled K1 channel Kir
3.1, channel activations were saturable functions of the appro-
priate chemokines (Fig. 1A and B). These currents were
completely blocked by pertussis toxin (Fig. 1C), consistent with
previous evidence for chemokine receptor coupling to Gi
proteins (38, 39). The properties of the conductance activated
by these ligands, including its K selectivity, voltage-
dependence, and sensitivity to block by Ba21 ions, are in
accord with the properties of Kir 3.1 (26, 27). In agreement
with this conclusion, oocytes lacking Kir 3.1 did not show
detectable currents. Because opening of Kir 3.1 channels is
mediated by direct interactions with Gbg-subunits that are
released when heterotrimeric G proteins are activated (28–
31), this assay reflects primary G protein activation and does
not depend on complex downstream signaling events such as
Ca21 f luxes or protein kinase cascades. Accordingly, the
response of the system is highly reproducible, making it
exceptionally useful for quantitative studies and for examining
modulations caused by gp120 glycoproteins of immunodefi-
ciency viruses.
Current responses desensitized in the continuous presence
of chemokine with time constants of 5–8 min and reached
steady-state levels that appeared receptor specific (e.g., see
Fig. 2). Moreover, when CXCR4, CCR5, and mGluR 2 were
coexpressed, heterologous desensitization was observed, as
FIG. 4. Extensive adsorption of monomeric T-cell-tropic or oligo-
meric M-tropic gp120s specifically and competitively antagonize
CXCR4 and CCR5 responses to chemokines in a tropism-specific
manner. All oocytes coexpressed CXCR4, CCR5, CD4, and Kir 3.1.
(A) Current records for two representative oocytes that were prein-
cubated with 0.4 mM gp120 IIIB for 1–2 h before voltage clamping and
superfusing with SDF-1a and MIP-1a at the concentrations indicated.
(B) Oocytes were similarly preincubated with 0.3 mM oligomeric
JR-FL gp120 for 1–2 h before analysis. (C) Monomeric gp120 IIIB
inhibition of CXCR4 activation by SDF-1a over a range of concen-
trations, without any effect on CCR5 responses to different concen-
trations of MIP-1a in the same oocytes. The oocytes were preincu-
bated with gp120 IIIB as in A, and measurements were recorded at
280 mV during voltage pulses (***P , 0.0002; **P , 0.0012; *P ,
0.05; each column represents mean 6 SEM; n 5 5–6). (D) Monomeric
gp120 Ba-L inhibition of CCR5 responses to different concentrations
of MIP-1a, without any significant effect on CXCR4 responses to
different concentrations of SDF-1a. The oocytes were preincubated
with gp120 Ba-L as described for A, and measurements were recorded
at 280 mV during voltage pulses (*P , 0.08; each column represents
mean 6 SEM; n 5 3).
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has been observed previously for coexpressed m-opioid and
serotonin-1A receptors in oocytes (32). Heterologous desen-
sitization implies that the oocyte down-modulatory mecha-
nism is induced by activation of all of these receptors. This
mechanism may promiscuously inhibit all G protein-coupled
receptors or it may inhibit a postreceptor step that is common
to their signaling pathways. In contrast, exposure of mamma-
lian cells to a chemokine causes rapid down-modulation and
cessation of its signal within approximately 1–2 min (40, 41),
without any desensitization of heterologous receptors (16). In
that case, activation of chemokine receptors results in their
rapid phosphorylation, binding of arrestins, and specific en-
docytosis (40–44).
Effects of gp120 on Signaling by CXCR4 and CCR5. In
contrast to the currents induced by chemokines in oocytes that
coexpress CD4 and Kir 3.1 with CXCR4 or CCR5, brief
superfusions with relatively high concentrations of highly
purified oligomeric or monomeric gp120 derived from T-cell-
tropic and M-tropic HIV-1 did not induce detectable signals in
these same oocytes (see Fig. 3C and D). Signaling was also
absent when applications of gp120 were increased up to 20 min
(results not shown). Nevertheless, it was conceivable that
gp120-induced receptor activation might occur more slowly
than the time scale of these experiments. This might occur as
a consequence of the relatively slow saturation of CD4 with
gp120 as demonstrated in Fig. 3B andyor to a slow recruitment
of coreceptors into ternary complexes. Clearly, however, our
gp120 preparations were competent for binding to CD4 (Fig.
1) and for CD4-dependent interactions with specific corecep-
tors (Fig. 4). Moreover, the oligomeric JR-FL gp120 prepa-
ration was generously donated by James Arthos and Anthony
Fauci, who recently reported that it induced rapid CCR5-
mediated Ca21 mobilization in activated CD4-positive human
T lymphocytes (16). Consistent with previous reports (8, 9,
11–13), our gp120 preparations also caused CD4-dependent
reductions in specific 125I-labeled chemokine binding to mam-
malian cells (S.L.K and D.K., unpublished data).
To address the absence of gp120-induced coreceptor acti-
vations in the oocyte superfusion assay, we preadsorbed
oligomeric or monomeric gp120s for 1–2 h before assaying
responses to chemokines. The baseline K1 currents were
unaffected by the adsorptions, confirming an absence of
chemokine receptor activation. Interestingly, however, exten-
sive preadsorption of gp120 from the T-cell-tropic HIV-1
isolate IIIB strongly inhibited subsequent response of CXCR4
to SDF-1a, whereas extensive preadsorption of oligomeric or
monomeric gp120 preparations from the M-tropic HIV-1
strains JR-FL and Ba-L inhibited CCR5-mediated signaling
(see Fig. 4). These gp120-induced inhibitions were CD4 de-
pendent and completely specific for the coreceptors that
mediate infections by these isolates of HIV-1. This specificity
clearly differs from activation-induced desensitization of sig-
naling that inhibits bystander G protein-coupled receptors (see
Fig. 2), suggesting instead a direct effect. In agreement with
this interpretation, the gp120 IIIB-mediated inhibition of
CXCR4 signaling was partially overcome at high concentra-
tions of SDF-1a (see Fig. 4C), implying that it involves a
competitive mechanism, and corresponding results were ob-
tained for the gp120 Ba-L inhibition of CCR5 responses to
MIP-1a (Fig. 4D). Together, these observations suggest that
gp120–CD4 complexes bind directly to the appropriate che-
mokine receptors to competitively inhibit their activations by
chemokines. This interpretation is concordant with previous
evidence that gp120–CD4 complexes bind to chemokine re-
ceptors (10) and partially displace 125I-labeled chemokines (8,
9, 12, 13). It should be emphasized, however, that in these
previous studies the residual affinities of ternary gp120–CD4-
coreceptor complexes for chemokines were not quantitatively
measured. Therefore, it remained theoretically possible that
these ternary complexes might prevent down-modulation and
be supersensitive rather than inhibited in their abilities to
signal in response to chemokines. Our evidence suggests that
the net effect of gp120 adsorption is to reduce rather than to
amplify signaling in response to chemokines.
Recently, Weissman et al. (16) reported that oligomeric or
monomeric gp120s from some M-tropic isolates of HIV-1 can
induce CCR5-mediated Ca21 mobilization in activated B10
lymphocytic cells and in activated CD4-positive T lympho-
cytes. Notably, however, gp120s from some viruses that use
CCR5 as a coreceptor failed to activate signaling, and gp120s
from T-cell-tropic HIV-1 isolates did not activate CXCR4.
Moreover, only a fraction (ca. 15–30%) of the cells in their
assay samples responded to gp120, and these responses gen-
erally appeared substantially weaker than responses of the
same cells to MIP-1b. In addition, Davis et al. (17) reported
that gp120 preparations from T-cell-tropic and M-tropic iso-
lates of HIV-1 increased the phosphorylation of Pyk2 tyrosine
kinase but did not induce detectable Ca21 mobilization in
activated CD4-positive T lymphocytes. In contrast, SDF-1a
and MIP-1b induced substantial Ca21 mobilization in the same
cells (17). These effects of gp120 are difficult to reconcile
because activation of phospholipase C with resultant Ca21
release is a proximal effect of activated Gbg-subunits (31, 39),
whereas Pyk2 phosphorylation is a downstream response that
depends on an increase in cytosolic Ca21 concentration (21,
22). Consequently, it is likely that gp120s used by Davis et al.
(17) induced Ca21 mobilization to a small but undetectable
extent in the cell population, implying that they were only weak
CXCR4 and CCR5 agonists or that they functioned as strong
agonists in only a small proportion of the chemokine-
responsive cells. Together, these results suggest that oligomeric
or monomeric gp120s might function to variable extents as
weak coreceptor agonists, perhaps only in proliferating cells at
one stage of the cell cycle or in the presence of Lck tyrosine
kinase or other lymphocyte accessory proteins. Our results are
compatible with these interpretations. It is important to em-
phasize that potential antagonist effects of gp120 were neither
examined nor excluded by these previous studies. Conceivably,
gp120s could be both weak agonists and strong antagonists of
coreceptor signaling, perhaps depending on specific intracel-
lular or extracellular factors such as proteoglycans. Presum-
ably, the structural organization of the virion envelope could
also influence the agonist and antagonist activities.
We believe that antagonist effects of oligomeric or mono-
meric gp120s on CXCR4 and CCR5 responses to chemokines
would very likely also occur in the natural cellular targets for
HIV-1 infections. Because these antagonisms appear to in-
volve direct interactions of gp120–CD4 complexes with
CXCR4 and CCR5 in a common membrane, they would be
expected to occur ubiquitously. Accordingly, previous evi-
dence has demonstrated gp120–CD4-coreceptor ternary com-
plexes (10) and gp120- and CD4-mediated competitive dis-
placement of 125I-labeled chemokines from CXCR4 and CCR5
in human lymphocytes and other cells (8, 9, 12, 13). However,
because of complexities in the signaling and desensitization
pathways of T lymphocytes as described above, and the
relatively low rate of gp120 binding onto cell surface CD4 (see
Fig. 3), we anticipate that antagonist effects of gp120s in
lymphocytes may prove difficult to unambiguously distinguish
from weak agonist-induced desensitizations. By either mech-
anism, however, a major expected consequence of gp120
adsoprtion would be attenuation of responses to specific
chemokines.
Based on these considerations, we conclude that gp120s
shed from virions and from infected cells may bind to unin-
fected CD4-positive cells and antagonize their responses to
specific chemokines. This could possibly have a major influ-
ence on immune and inflammatory responses of infected
individuals. Further investigations will be needed to under-
stand the importance of this inhibition and of the recently
Biochemistry: Madani et al. Proc. Natl. Acad. Sci. USA 95 (1998) 8009
reported gp120-mediated CXCR4 and CCR5 activations (16,
17) on the development of HIV-1-induced disease.
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